We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Premaitha | LSE:NIPT | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.10 | 9.00 | 9.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/10/2016 07:25 | 27 Sept 2016 Shareprophets, Strong Buy | deanroberthunt | |
27/10/2016 07:23 | 'Despite short-term distractions caused by the infringement claims of Illumina, Premaitha is building a highly compelling business, which will be global within the next twelve months.' | timojelly | |
27/10/2016 07:22 | Revenue first half of previous year £600k! | dave444 | |
27/10/2016 07:21 | target share price end 2018 75-100p | deanroberthunt | |
27/10/2016 07:20 | 'The international landscape for non-invasive prenatal testing is evolving very considerably in Premaitha's favour' | timojelly | |
27/10/2016 07:20 | I believe this is a similar story to Tristel, which now has sales of nearly £20m, profits of £3-4m and pays a dividend.....sp has 7-8 bagged from year past lows in 2013... NIPT, however, has far more potential imvho | deanroberthunt | |
27/10/2016 07:20 | You would expect that - they did not sell much in the equivalent period last year! | dave444 | |
27/10/2016 07:18 | `I am pleased to note that trading in the first half of the current financial year was materially above the equivalent period last year, positioning Premaitha comfortably on track to outperform the IONA(R) test's first full commercial year.` | timojelly | |
27/10/2016 07:16 | diamond in the AIM rough | deanroberthunt | |
27/10/2016 07:14 | added some yesterday, hopefully, it doesn't bounce early doors, will add some more | deanroberthunt | |
27/10/2016 07:14 | Cracking agm statement. Bring on the newsflow "We are very encouraged by the growth we have seen in the Middle East and we are focusing substantial efforts within this region and in Asia Pacific and hope to announce shortly a number of sizeable commercial agreements." | brainspark1 | |
27/10/2016 07:14 | cash flow positive early 2017 | deanroberthunt | |
27/10/2016 07:12 | Very very positive. READ It! Sub 20p will very soon be history.... Roll in 50p. | timojelly | |
27/10/2016 07:04 | silly cheap, market is irrational, but not forever.....hold, live long and prosper. | deanroberthunt | |
27/10/2016 00:22 | If you miss the AGM tomorrow but would like to meet the company and ask the CEO a few questions, Premaitha are presenting at the ShareSoc seminar in Leeds on the 3rd November - here's the link - hxxp://www.sharesoc. | quinag | |
26/10/2016 17:33 | Black - yes, do the opposite in most cases and he's worth following - imho. | gooosed | |
26/10/2016 16:34 | Ah yes TW, a lot of people here quids down thanks to him. | blackss | |
26/10/2016 15:40 | No one is admitting to attend the AGM (too ashamed?). Hopefully there will be some feedback. There has been a lot of opinions expressed on all boards (mostly negative) so hope we don't just let the BOD just post 'all motions passed. At least TW will have plenty to say next week. | ewads | |
26/10/2016 11:21 | Anyone attending AGM ? | gooosed | |
26/10/2016 08:40 | when the case is sorted this'll be over 25p | deanroberthunt | |
25/10/2016 18:09 | Illumina being investigated again..investors not happy it seems! NEW YORK, Oct. 21, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Illumina Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484. The investigation concerns whether Illumina and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. | hjb1 | |
25/10/2016 16:28 | Sequenom has prelim injunction filed today against Amedes (+1 other) in Germany related to their Fetalis NIPT test base on Ariosa technology. Do we know if these guys are a Premaitha customer? | philburt | |
21/10/2016 14:30 | More shares for the boys while Genoma is doing the heavy lifting. Give them a good kicking at the AGM folks | hurricane. | |
21/10/2016 11:08 | Your forgetting the shares at 6.5p and 8p that's over 40 mil plus | thinkbig? |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions